Gilbert R Kaufmann
Affiliation: University Hospital
- Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapyGilbert R Kaufmann
Division of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland
Clin Infect Dis 41:361-72. 2005..We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration...
- CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapyNina Khanna
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland
Clin Infect Dis 47:1093-101. 2008....
- Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infectionGilbert R Kaufmann
Division of Infectious Diseases, University Hospital, Basel, Switzerland
Antivir Ther 9:263-74. 2004..Information about the virological response to sequential highly active antiretroviral therapy (HAART) for HIV infection is limited. The virological response to four consecutive therapies was evaluated in the Swiss HIV Cohort...
- CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort StudyGilbert R Kaufmann
Basel Center for HIV Research, Division of Infectious Diseases, University Hospital, Basel, Switzerland
Arch Intern Med 163:2187-95. 2003..Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART...
- Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and deathGilbert R Kaufmann
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland
AIDS 25:441-51. 2011..Interruptions of ART are still frequent. The long-term effect on CD4 T-cell recovery and clinical events remains unknown...
- Immunological recovery and antiretroviral therapy in HIV-1 infectionManuel Battegay
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
Lancet Infect Dis 6:280-7. 2006..In addition, immune reconstitution disease, an inflammatory syndrome associated with immunological recovery occurring days to weeks after the start of antiretroviral therapy, is briefly described...
- Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytesNatasha Hansjee
Institute for Medical Microbiology, University of Basel, Division of Infectious Diseases, Department of Internal Medicine, University Hospital Basel, Switzerland
J Acquir Immune Defic Syndr 36:671-7. 2004..The significant relationship between residual T-lymphocyte apoptosis and CD4 T-cell recovery suggests that persistent apoptosis may impede immune restoration...
- Productivity costs and determinants of productivity in HIV-infected patientsPedram Sendi
Division of Infectious Diseases, Basel University Hospital, Basel, Switzerland
Clin Ther 26:791-800. 2004..In HIV-infected patients, reduced ability to work may be an important component of the societal costs of this disease. Few data about productivity costs in HIV-infected patients are available...
- Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countriesGilbert R Kaufmann
Basel Center for HIV Research, Division of Infectious Diseases, University Hospital Basel, Switzerland
Expert Opin Investig Drugs 11:1303-13. 2002....
- Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversionDon E Smith
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
AIDS Res Hum Retroviruses 19:189-99. 2003..Despite poorer prognostic markers at baseline ES subjects achieved responses similar to those of LS subjects after 1 year of treatment...
- Gynecomastia and potent antiretroviral therapyChristoph Strub
AIDS 18:1347-9. 2004
- Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacyAngela C Huttner
University Hospital of Zurich, Zurich, Switzerland
AIDS 21:939-46. 2007..We examined the predictive factors for this phenomenon and assessed its impact on clinical progression during treatment in a large patient cohort...
- Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infectionYvonne Märki
J Infect Dis 185:1844-6. 2002
- The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapyGilbert R Kaufmann
National Centre in HIV Epidemiology and Clinical Research, Sydney NSW, 2010, Australia
AIDS 16:359-67. 2002..To study the long-term immunological recovery in HIV-1-infected individuals receiving potent antiretroviral therapy (ART)...
- Dynamics of T cells and TCR excision circles differ after treatment of acute and chronic HIV infectionSharon R Lewin
Department of Microbiology and Immunology, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia
J Immunol 169:4657-66. 2002....